NCT05602363 - AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions

B-cell MalignancyChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaWaldenstrom MacroglobulinemiaMantle Cell LymphomaMarginal Zone LymphomaFollicular LymphomaNon-Hodgkin Lymphoma

Interventions

DRUG

Docirbrutinib

oral tablet, twice daily

Trial Locations (11)

11590

RECRUITING

Clinical Research Alliance, Inc., Westbury

21201

RECRUITING

University of Maryland Medical Center - Greenebaum Comprehensive Cancer Center, Baltimore

27705

RECRUITING

Duke University, Durham

33140

RECRUITING

Mount Sinai Comprehensive Cancer Center, Miami Beach

33612

RECRUITING

Moffitt Cancer Center, Tampa

43537

RECRUITING

Taylor Cancer Research Center, Maumee

53266

RECRUITING

The Medical College of Wisconsin, Milwaukee

60661

RECRUITING

Northwestern Memorial Hospital, Chicago

77030

RECRUITING

University of Texas MD Anderson Cancer Center, Houston

92868

RECRUITING

UC Irvine Health, Orange

01655

RECRUITING

University of Massachusetts Memorial Medical Center, Worcester